Roanna Ruiz
Stock Analyst at Leerink Partners
(0.48)
# 3,044
Out of 4,413 analysts
50
Total ratings
21.88%
Success rate
-28.37%
Average return
Main Sectors:
14 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Initiates: Outperform | $14 | $6.40 | +118.75% | 1 | Apr 5, 2024 | |
| SPRY ARS Pharmaceuticals | Upgrades: Outperform | $6 → $18 | $8.70 | +106.90% | 2 | Mar 5, 2024 | |
| UTHR United Therapeutics | Initiates: Outperform | $330 | $234.33 | +40.83% | 1 | Feb 5, 2024 | |
| CYTK Cytokinetics | Initiates: Outperform | $58 | $61.32 | -5.41% | 1 | Aug 15, 2023 | |
| CORT Corcept Therapeutics | Initiates: Market Perform | $25 | $23.32 | +7.20% | 1 | Apr 11, 2023 | |
| ENTA Enanta Pharmaceuticals | Reiterates: Market Perform | $49 | $13.74 | +256.62% | 10 | Feb 9, 2023 | |
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $6 → $5 | $1.75 | +185.71% | 4 | Jan 27, 2023 | |
| VIR Vir Biotechnology | Maintains: Outperform | $45 → $43 | $8.46 | +408.27% | 3 | Jan 27, 2023 | |
| SCPH scPharmaceuticals | Maintains: Outperform | $12 → $13 | $4.47 | +190.83% | 5 | Jan 27, 2023 | |
| AVIR Atea Pharmaceuticals | Maintains: Market Perform | $8 → $6 | $3.70 | +62.16% | 6 | Jan 27, 2023 | |
| NAMS NewAmsterdam Pharma Company | Initiates: Outperform | $19 | $21.81 | -12.88% | 1 | Dec 20, 2022 | |
| LNTH Lantheus Holdings | Maintains: Outperform | $110 → $120 | $66.54 | +80.34% | 3 | Nov 15, 2022 | |
| ALGS Aligos Therapeutics | Maintains: Market Perform | $3 → $2 | $0.77 | +161.44% | 7 | Nov 3, 2022 | |
| AMRN Amarin Corporation | Maintains: Market Perform | $3 → $2 | $0.92 | +117.18% | 5 | Oct 19, 2022 |
Ardelyx
Apr 5, 2024
Initiates: Outperform
Price Target: $14
Current: $6.40
Upside: +118.75%
ARS Pharmaceuticals
Mar 5, 2024
Upgrades: Outperform
Price Target: $6 → $18
Current: $8.70
Upside: +106.90%
United Therapeutics
Feb 5, 2024
Initiates: Outperform
Price Target: $330
Current: $234.33
Upside: +40.83%
Cytokinetics
Aug 15, 2023
Initiates: Outperform
Price Target: $58
Current: $61.32
Upside: -5.41%
Corcept Therapeutics
Apr 11, 2023
Initiates: Market Perform
Price Target: $25
Current: $23.32
Upside: +7.20%
Enanta Pharmaceuticals
Feb 9, 2023
Reiterates: Market Perform
Price Target: $49
Current: $13.74
Upside: +256.62%
Xeris Biopharma Holdings
Jan 27, 2023
Maintains: Outperform
Price Target: $6 → $5
Current: $1.75
Upside: +185.71%
Vir Biotechnology
Jan 27, 2023
Maintains: Outperform
Price Target: $45 → $43
Current: $8.46
Upside: +408.27%
scPharmaceuticals
Jan 27, 2023
Maintains: Outperform
Price Target: $12 → $13
Current: $4.47
Upside: +190.83%
Atea Pharmaceuticals
Jan 27, 2023
Maintains: Market Perform
Price Target: $8 → $6
Current: $3.70
Upside: +62.16%
NewAmsterdam Pharma Company
Dec 20, 2022
Initiates: Outperform
Price Target: $19
Current: $21.81
Upside: -12.88%
Lantheus Holdings
Nov 15, 2022
Maintains: Outperform
Price Target: $110 → $120
Current: $66.54
Upside: +80.34%
Aligos Therapeutics
Nov 3, 2022
Maintains: Market Perform
Price Target: $3 → $2
Current: $0.77
Upside: +161.44%
Amarin Corporation
Oct 19, 2022
Maintains: Market Perform
Price Target: $3 → $2
Current: $0.92
Upside: +117.18%